BridgeBio Pharma, Inc. 8-K

What Happened

BridgeBio Pharma, Inc. filed an 8-K reporting that Dr. Randal W. Scott resigned from the Board effective June 22, 2026 (the date of the 2026 Annual Meeting), and that stockholders elected three Class I directors to three‑year terms: James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D. A total of 175,706,357 shares were present or represented by proxy out of 195,806,242 entitled to vote.

At the June 22, 2026 Annual Meeting the company reported results on several governance proposals: stockholders approved the non‑binding advisory vote on named executive officer compensation and selected an annual frequency for future advisory votes; ratified Deloitte & Touche LLP as independent auditor for fiscal 2026; and approved an amendment to the company’s 2021 Stock Option and Incentive Plan to add 2,000,000 shares (the amendment is filed as Exhibit 10.1).

Key Details

• Director resignation: Dr. Randal W. Scott resigned effective June 22, 2026; resignation was not due to any disagreement with the company.
• Director election vote counts: James C. Momtazee — 156,790,852 for / 4,316,018 withheld; Frank P. McCormick — 153,020,532 for / 8,086,338 withheld; Hannah A. Valantine — 129,081,930 for / 32,024,940 withheld. (14,599,487 broker non‑votes on these director matters.)
• Executive compensation votes: Advisory approval — 152,949,577 for, 6,938,080 against, 1,219,213 abstentions; frequency vote favored every 1 year (154,371,970 for).
• Other votes: Auditor ratified — 175,420,234 for; stock‑plan amendment to add 2,000,000 shares approved — 132,402,786 for / 27,350,537 against / 1,353,547 abstentions. Amendment filed as Exhibit 10.1.

Why It Matters

Board membership and governance votes affect company oversight and shareholder relations. The resignation of Dr. Scott and the election results finalize the Class I director slate through 2029. The strong outcome for annual advisory compensation votes signals shareholders’ preference for yearly say‑on‑pay votes and the company’s plan to follow that preference. Approval of the 2,000,000‑share increase to the stock option and incentive plan authorizes additional equity awards that may be used for employee and executive compensation, which can have a dilutive effect over time. Ratification of Deloitte as auditor is a routine governance item confirming the firm for fiscal 2026.